WO2000051563A1 - Compositions pharmaceutiques pour l'administration orale comprenant un benzamide et au moins un promoteur d'absorption - Google Patents
Compositions pharmaceutiques pour l'administration orale comprenant un benzamide et au moins un promoteur d'absorption Download PDFInfo
- Publication number
- WO2000051563A1 WO2000051563A1 PCT/FR2000/000504 FR0000504W WO0051563A1 WO 2000051563 A1 WO2000051563 A1 WO 2000051563A1 FR 0000504 W FR0000504 W FR 0000504W WO 0051563 A1 WO0051563 A1 WO 0051563A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutical composition
- composition according
- amisulpride
- active principle
- absorption promoter
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0007—Effervescent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
Definitions
- the present invention relates to pharmaceutical compositions for oral administration comprising an active principle of the family of benzamides as well as at least one absorption promoter.
- Benzamides are chemical compounds whose structure includes the following motif:
- benzamides can be administered orally.
- the Applicant has observed that the oral administration of certain benzamides could lead to an absorption of the order of 30 to 65%, corresponding to an incomplete absorption.
- absorption is understood here to mean the fraction of the active principle which crosses the intestinal barrier.
- This incomplete absorption can be the result of several factors, among which we can cite: poor solubility or very slow dissolution of the active ingredient; instability of the active ingredient, either over the entire length of the gastrointestinal tract, or in only one of its parts; the enzymatic degradation in the mucosa of the active ingredient; slow or incomplete absorption of the active ingredient due to slow passive diffusion through the intestine or, in the case of an active mechanism, saturation of the transport system.
- permeability and secretory flow which are defined as follows in the framework of the present invention:
- - permeability is defined as the fraction of dose of the active ingredient having crossed the intestinal barrier in the intestinal lumen direction towards the intercellular space and the cells.
- the secretory flow is defined as being the fraction of dose of the active principle having crossed the intestinal barrier in the opposite direction.
- the Applicant has considered improving the absorption of benzamides by combining them with an absorption promoter.
- the invention consists of a pharmaceutical composition for oral administration comprising an active principle consisting of a benzamide or a pharmacologically salt thereof and at least one absorption promoter.
- composition according to the invention makes it possible to reduce the doses administered as benzamides, for a given effective dose.
- This composition also makes it possible to reduce the number of daily doses.
- composition according to the invention makes it possible to reduce the interindividual variability of the circulating levels of the active principle, for a given dose.
- the benzamides are substrates of the active efflux system P-glycoprotein.
- This active efflux system P-glycoprotein can be at the origin, for certain active principles, of a weak intestinal absorption, because contributing to a high secretory flow.
- P-glycoprotein (Pgp) involved in membrane transport, is located in particular in the wall of the intestine (epithelium with brush border). Its role is in particular to prevent intracellular penetration of its substrates by rejecting them in the intestine. These substrates are therefore subjected to a secretory flow which prevents them from crossing the intestinal mucosa and consequently affects their absorption.
- any substance suitable for increasing the permeability and / or inhibiting the secretory flow is suitable, its action being able to be limited to increasing the permeability or decreasing the secretory flow or else its action being able to be mixed.
- P-glycoprotein inhibitors can be used, in the context of the present invention, as promoters absorption.
- sucrose esters especially the stearate-pal itate sucrose, sucrose monopalmitate such as sucrose ester ® 15, sucrose monostearate; alkyl esters of polyoxyethylene sorbitan, particularly polyoxyethylene sorbitan monooleate 20 (polysorbate 80) such as Tween 80 ®, polyoxyethylene sorbitan monolaurate 20 (polysorbate 20) and polyoxyethylene sorbitan monostearate 20 (polysorbate 60); polyethoxylated castor oils, hydrogenated or not, in particular polyethoxylated hydrogenated castor oils-40 such as Cremophor ® RH 40 and -60 such as Cremophor ® RH 60; the polyethoxylated castor oils, particularly castor oil polyoxyethylene-35 such as Cremophor ® EL; d- -tocopherol polyethylene glycol succinate (TPGS or vitamin E TPGS); poloxamers,
- the invention is more particularly suitable for the active principles which are sulpiride, amisulpride, their pharmaceutically acceptable salts, their enantiomers and the salts of these enantiomers.
- benzamides can be used in the context of the present invention such as lintopride, bromopride, alizapride, R-zacopride, tiapride, sultopride, remoxipride and veralipride.
- Certain benzamides are useful as an active ingredient in medicaments intended for the treatment, in particular, of disorders of the central nervous system.
- the invention is particularly suitable for
- the preferred tartrate is D- (-) -tartrate from (S,) ( _ ) -amisulpride, in other words [S- (R *, R *)] -2, 3-dihydroxybutanedioate from (S) - (- ) -4-amino- N- [(1-ethylpyrrolidin-2-yl) methyl] -5- (ethylsulfonyl) -2-methoxybenzamide.
- Amisulpride is a neuroleptic used in the treatment of psychosis, more particularly in the treatment of paranoid and productive schizophrenia, acute delusional psychosis, as well as in the treatment of deficit states of schizophrenia, residual psychotic changes and states of inhibition with slowdown. Amisulpride is also useful in the treatment of dysthymia, autism, neuroleptic-induced tardive dyskinesia, Gilles de la Tourette's disease, manic or depressive symptoms in patients with manic-depressive psychosis (PMD), acute delirium, migraine and drug addiction.
- PMD manic-depressive psychosis
- compositions according to the invention make it possible to increase the absorption of benzamides through the intestinal mucosa by at least 10%.
- compositions according to the invention can be used in any galenical formulation.
- compositions according to the invention can take the form of solutions, suspensions, emulsions, microemulsions, capsules, capsules, sachets, tablets, effervescent tablets, multilayer tablets, etc., these compositions possibly being immediate release or modified.
- composition according to the invention may consist of a capsule comprising the combination of absorption promoter and active principle.
- an immediate release tablet it is possible to compress granules comprising the active principle, the usual excipients of diluents, lubricants, disintegrants, binders, etc. type and one or more absorption promoters. Alternatively, these granules can be placed in sachets or capsules.
- immediate-release formulations are also known in the present invention.
- These pharmaceutical compositions can in particular take the form (1) of a lipid solution, (2) of an emulsion or microemulsion and (3) of a self-emulsifying mixture.
- absorption promoter (s) are then for example incorporated into these pharmaceutical compositions according to one of the following alternatives:
- the absorption promoter (s) are dissolved in the oil or the lipid mixture.
- the absorption promoter (s) are dissolved in the oily phase and form part of the oily phase. They can be added to the oily components or surfactants of the composition.
- the absorption promoter (s) are dissolved in the self-emulsifying mixture. They can be added to the oily components or surfactants of the composition.
- compositions and in particular of the lipophilic phase are described more precisely below.
- the lipophilic phase can be solid or, preferably, liquid at room temperature.
- the lipophilic phase may consist of (i) one or more fatty acids, (ii) one or more oils or triglycerides, such as transesterified and / or polyethoxylated or synthetic oils, animal or vegetable, or (iii) a mixture comprising two or more in addition to the compounds mentioned under points (i) and (ii) in particular, a mixture comprising a fatty acid and an oil.
- fatty acids mention may be made of those comprising from 8 to 22 carbon atoms, in particular capric, caprylic, lauric, oleic, arachidonic, linolenic, linoleic or ricinoleic acids.
- vegetable oils (ii) mention may be made of olive, peanut, soybean, rapeseed, palm, sesame, grapeseed, corn, walnut or sunflower oils.
- triglycerides (ii) include capric triglycerides, caprylic such as Captex ® sold by Abitec or Miglyol ® marketed by Hüls.
- transesterified and / or polyethoxylated vegetable oils mention may be made of polyethoxylated olive oils, polyethoxylated sunflower oils, polyethoxylated palm oils or polyethoxylated castor oils.
- liver oils in particular cod or halibut liver oils.
- a preferred lipophilic phase consists of fatty acids or esters of fatty acids with a C 8 -C 12 medium chain such as capric, caprilic or lauric acids or their combinations.
- the pharmaceutical composition according to the invention when in the form of a lipid solution (1), it essentially comprises a lipophilic phase, generally consisting of at least one fatty acid and / or at least one oil, as defined above for the lipophilic phase, the active principle being dissolved in this lipophilic phase.
- a lipid solution is substantially free of hydrophilic phase.
- the lipophilic phase of the lipid solution can for example consist of fatty acids or esters of C 8 -C 12 medium chain fatty acids such as capric, caprilic or lauric acids or combinations thereof and the fatty acid may be oleic acid.
- an emulsion or microemulsion comprises a hydrophilic phase and at least one surfactant.
- the emulsion can be of the water in oil (W / O) type or, preferably, oil in water (O / W).
- the emulsion can be of the submicron emulsion type.
- Such an emulsion has a discontinuous phase in the form of particles with an average diameter of less than 1 ⁇ m, generally between 0.3 and 0.7 ⁇ m.
- microemulsion is preferred, which is defined as having a discontinuous phase generally in the form of particles with an average diameter of between 0.02 and 0.250 ⁇ m.
- the discontinuous or dispersed phase consists of these particles or droplets.
- the hydrophilic phase may contain and / or consist of one or more compounds chosen from alcohols such as glycerol, propylene glycol, polyethylene glycols whose molecular weight is between 100 and 3000, and water.
- alcohols such as glycerol, propylene glycol, polyethylene glycols whose molecular weight is between 100 and 3000, and water.
- water is preferred.
- the dispersed phase of an emulsion thus described can represent from 5 to 30% by weight, generally from 10 to 20% by weight of the total weight of the emulsion.
- the surfactant is chosen according to the nature of the emulsion.
- a person skilled in the art knows, in particular according to his HLB (Hydrophilic-Lipophilic Balance), which surfactant to choose to obtain a W / O, O / W emulsion or a microemulsion.
- HLB Hydrophilic-Lipophilic Balance
- surfactant which may be suitable for any emulsion, mention may be made of sorbitan esters and polyoxyethylenated sorbitan esters, such as those sold under the brands T een® and Span®, in particular polysorbate 80.
- lecithins animal or vegetable origin polyoxyethylenated castor oils, such as those sold under the brand Cremophor®, sucrose and fatty acid esters (or sucroesters), fatty alcohol and polyethylene glycol esters, acid esters fatty acids and polyethylene glycol, bile acids, monoglycerides, diglycerides or acetylated or polyethoxylated derivatives of these compounds can also be used as surfactants, alone or as a mixture.
- monoglycerides diglycerides or acetylated or polyethoxylated derivatives of these compounds, mention may in particular be made of those comprising, respectively, one or two fatty chains comprising from 8 to 24 carbon atoms, and more particularly, those marketed by companies.
- Capmul® and Myvacet® Abitec and Eastman under the brands Capmul® and Myvacet®, in particular mono glycerol caprylate, mono glycerol stearate, monoacetylated monoglycerides and diacetylated monoglycerides
- An emulsion according to the invention can comprise from 0.01 to 5% by weight of surfactants relative to the dispersed phase.
- the proportion of water in the formulation is adjusted so as to ensure the solubilization of the active principle.
- the total amount by weight of absorption promoter and surfactant is 2 to 15 times greater compared to the dispersed phase (whether it is water or oil).
- the amount of absorption promoter can represent from 0.5 to 10 times the amount by weight of surfactant.
- self-emulsifying mixture is understood to mean, also called pre-emulsion or pre-microemulsion, a mixture consisting of a lipophilic phase with at least one surfactant, this mixture possibly forming an emulsion by simple mechanical stirring with an aqueous phase.
- a self-emulsifying mixture according to the invention can, after oral administration, form emulsions with the hydrophilic phases of the organism.
- the surfactants constituting such a self-emulsifying mixture can be chosen from the same surfactants as those suitable for emulsions or microemulsions (2).
- a preferred lipophilic phase consists of fatty acids or esters of fatty acids with a C 8 -C 12 medium chain such as capric, caprilic or lauric acids or their combinations.
- the total amount by weight of absorption promoter and surfactant of the self-emulsifiable mixture can be between 0.5 and 6 times greater relative to the dispersed phase (whether it is water or l 'oil) .
- the amount of absorption promoter can represent from 0.5 to 10 times the amount by weight of surfactant.
- compositions according to the invention (1), (2) or (3) can also comprise pharmaceutically acceptable excipients, such as diluents, preserving agents, osmotic agents, antioxidants, thickening agents, agents stabilizers, viscosity-lowering agents such as ethanol, gelling agents and pH buffers.
- pharmaceutically acceptable excipients such as diluents, preserving agents, osmotic agents, antioxidants, thickening agents, agents stabilizers, viscosity-lowering agents such as ethanol, gelling agents and pH buffers.
- compositions of the invention can be prepared in a conventional manner for a person skilled in the art.
- a lipid solution (1) can be prepared by dissolving the active principle in the lipophilic phase with stirring. If necessary, other excipients can then be added, such as those mentioned above.
- the lipophilic phase containing the absorption promoter can be introduced with stirring into the hydrophilic phase in which the surfactant (s) have been added beforehand, and where appropriate, hydrophilic excipients.
- the active principle is added beforehand in one of the two phases according to its hydrophilic or lipophilic affinity. Agitation can be carried out using a device of the Ultra-Turrax® type.
- the emulsion thus obtained can be refined by means of a very high pressure die, for example of the APV-Gaulin® type.
- the oily phase, the absorption promoter and the surfactant are mixed with water by simple stirring, the active principle being introduced beforehand in the phase with which it has the greatest affinity .
- a self-emulsifiable mixture (3) can be prepared conventionally, by introducing, with stirring, the surfactant (s) and the absorption promoter required in a lipophilic phase containing the active principle.
- compositions (1), (2) or (3) can be presented in liquid form, divided or not, accompanied or not by a dosing device such as a spoon, in gelled form, in the form of soft capsules, of globules or, preferably, in the form of capsules.
- a dosing device such as a spoon
- gelled form in the form of soft capsules, of globules or, preferably, in the form of capsules.
- capsules can consist of gelatin or starch and are usually sealed in a conventional manner.
- the absorption promoter may advantageously be vitamin E TPGS or a TPGS mixture monopalmitate and sucrose such as sucrose ester 15 ®.
- compositions comprise from 1 to 30% by weight of active principle and from 10 to 80% by weight of absorption promoter (S) mentioned above.
- compositions (1), (2) and (3) the self-emulsifying mixtures leading to a microemulsion for the base active ingredients or a microemulsion in the case of the active ingredient salts are preferred.
- the combination with a benzamide of an absorption promoter according to the present invention is also suitable for dosage forms intended for modified release.
- an absorption promoter in this type of pharmaceutical composition can then be envisaged by the simple addition of a proportion of absorption promoter not exceeding 20% of the total of the components of said composition.
- the absorption promoter can be incorporated in a separate phase of the pharmaceutical composition, for example in the case of a tablet, in an additional layer.
- prolonged-release compositions suitable for carrying out the present invention there may also be mentioned a capsule composed of two different types of spheroids (i) and (ii), (i) comprising the active principle and (ii) comprising an absorption promoter, (i) and (ii) are coated so as to control the diffusion.
- This coating can in particular be formed of polymers such as 1 ethylcellulose, methylmethacrylate copolymers such as Eudragit ® RS, Eudragit ® RL, Eudragit ® NE commercialized by Rohm Pharma.
- the coating of each type of spheroid is chosen so that the release rates of the active principle and of the absorption promoter are similar.
- the coating can be carried out according to methods known to those skilled in the art, through the use, for example, of a fluidized air bed device (such as Glatt GPCG3) or a turbine (such as Accelacota).
- a bilayer prolonged-release tablet is suitable for using the compositions according to the present invention, where a first layer comprises the active principle and a release-modifying excipient and where the second layer comprises the absorption promoter and a release-modifying excipient, identical or different from that of the first layer.
- This release-modifying excipient can be a hydrophilic polymer or a lipid excipient.
- hydrophilic polymers such as methyl hydroxyethylcellulose, carboxymethylcellulose and its salts such as sodium carboxymethylcellulose or calcium carboxymethylcellulose, and preferably hydroxypropylcellulose, hydroxypropylmethylcellulose and mixtures of hydroxypropylcellulose and hydroxypropyl methylcellulose; natural polysaccharides such as alginates, xanthan gum, guar gum, gum arabic or locust bean gum; and synthetic hydrophilic polymers such as polyvinylpyrrolidones, polymers derived from acrylic and methylacrylic acids and their salts such as polyacrylates, in particular those marketed under the trademark Carbopol ® or the amino acid polymers such as polylysine.
- cellulose derivatives such as methyl hydroxyethylcellulose, carboxymethylcellulose and its salts such as sodium carboxymethylcellulose or calcium carboxymethylcellulose, and preferably hydroxypropylcellulose, hydroxypropylmethylcellulose and mixtures of hydroxypropylcellulose and hydroxypropyl methylcellulose
- lipid excipients mention may be made of hydrogenated castor oil, beeswax, carnauba wax, glycerol trimyristate, glycerol trilaurate, glycerol tristearate, cetyl palmitate and glycerol behenate.
- a formulation is chosen which tends towards approaching release rates of the active principle and of the absorption promoter.
- compositions according to the invention comprise from 5 to 90% by weight of active principle and from 5 to 80% by weight, preferably from 10 to 50% by weight of absorption promoter.
- the quantity in amisulpride base equivalent is between 20 and 400 mg, preferably between 100 and 400 mg.
- the amount in equivalent (S) (-) -amisulpride base is between 10 and 400 mg, preferably between 50 and 300 mg.
- the amount in equivalent sulpiride base is between 50 and 500 mg, preferably between 100 and 500 mg.
- the absorption promoters indicated in tables 1 and 2 and tested at the concentration of 0.16 mg / ml, increase the permeability of amisulpride and of D- (-) -tartrate of (S) (-) - amisulpride in the apical to basal direction by a factor of 2 to 3 and decrease the secretory flux by a factor of 3 to 4.
- the decrease in secretory flux is of a lesser degree for Sucroester ® 15.
- the results are similar for promoter concentrations 10 times lower or higher.
- the permeabilities are relativized with respect to the control and expressed as a percentage.
- FIG. 1 represents the dissolution profile of a capsule containing 140 mg of D- (-) -tartrate from (S) (-) -amisulpride of Example 3, at pH 2.
- FIG. 2 represents the dissolution profile of a capsule containing 200 mg of amisulpride from Example 4, at pH 2 and pH 7.5.
- FIG. 3 represents the dissolution profile of a capsule containing 140 mg of D- (-) -tartrate from (S) (-) -amisulpride of Example 5, at pH 2.
- the granules can then be distributed in sachets for immediate release.
- the same granules can be divided into capsules for a dose of 70 mg of D- (-) -tartrate of (S) (-) -amisulpride (i.e. 50 mg of (S) (-) -amisulpride base) for immediate release.
- Tablets can also be prepared for modified release, containing 70 mg of (S) (-) -amisulpride D- (-) -tartrate, by compression with a rotary machine in 8R8 format.
- the active ingredient, tartaric acid, hydroxyprolpylmethylcellulose, lactose and the sucrose ester are mixed and forms granules.
- the granules are dried in an oven at 55 ° C, then calibrated on a 0.8 mm grid.
- Sodium bicarbonate is added to the granule and mixed in the Turbula ® mixer for 10 min.
- Colloidal silica and magnesium stearate are added to lubricate the granule. They are mixed in Turbula ® for 10 min. The mixture is compressed in 11R11 format.
- Example 3 Oil-in-water microemulsion containing D- (-) -tartrate from (S) (-) -amisulpride
- the absorption promoter / surfactant / oil mixture is prepared with magnetic stirring.
- the D- (-) -tartrate of (S) (-) -amisulpride is dissolved in the quantity of water used in the composition, and the aqueous solution is added to the initial mixture with stirring.
- the mixture obtained is pasty.
- the dissolution profile of the formulation obtained is measured in 1000 ml of 0.01 M hydrochloric acid using the rotary vane apparatus described in the European Pharmacopoeia.
- the agitation is 50 rpm and the temperature 37 ° C.
- the amount of D- (-) -tartrate from (S) (-) - dissolved amisulpride is determined by measuring the optical density of the solution at 254 nm. Dissolution is rapid ( Figure 1).
- Triglycerides capric, Huiui 20,0 100,0 caprylic 1
- the absorption promoter / surfactant / oil mixture is prepared with magnetic stirring. Add Amisulpride to the mixture with magnetic stirring so as to suspend the active principle.
- the dissolution profile of the formulation was measured using the rotary vane apparatus described in the European Pharmacopoeia, the agitation being 50 rpm.
- the dissolution medium is 0.01 M hydrochloric acid and a pH 7.5 phosphate buffer, 0.015 M concentration. two cases, a volume of hydrochloric acid of 1000 ml is used.
- the amount of dissolved amisulpride is determined by measuring the optical density of the solution at 254 nm. Dissolution is rapid at both pH ( Figure 2).
- Example 5 Water-in-oil microemulsion containing D- (-) -tartrate from (S) (-) -amisulpride
- TPGS d- ⁇ -tocopherol-polyethylene glycol 1000 succinate
- Eastman 3 Capmul ® MCM marketed by Abitec, USA
- the absorption promoter / surfactant / oil mixture is prepared with magnetic stirring.
- the D- (-) -tartrate of (S) (-) -amisulpride is dissolved in the quantity of water used in the composition, and the aqueous solution is added to the initial mixture with magnetic stirring. A clear liquid is obtained.
- Example 6 Self-emulsifying mixture leading to an oil-in-water microemulsion containing (S) (-) -amisulpride base in the form of a capsule:
- Aapmul ® MCM marketed by Abitec, USA 2 Captex ® 355, marketed by Abitec, USA
- the mixture of excipients is prepared with magnetic stirring while maintaining in a water bath at 50 ° C.
- the active ingredient is added, and the mixture is put in capsule.
- the capsule is introduced into 500 ml of 0.01M hydrochloric acid at 37 ° C, stirred at 50 rpm.
- the droplet size was measured by a Nanosizer laser device (Malvern Instruments): it is 23 nm.
- the dissolution carried out under the preceding conditions is rapid: 63% of the active principle is dissolved in 10 min.
- Example 7 Self-emulsifying mixture leading to an oil-in-water microemulsion containing
- Mono-di- Agent 18 108 glycerides surfactant of capric, caprilic acid 2
- the mixture was prepared identically to the previous example, the sucrose ester ® 15 being introduced just before the active ingredient. A suspension is obtained and put in capsule.
- Example 8 Self-emulsifying mixture leading to an oil-in-water microemulsion containing (S) (-) -amisulpride base in the form of a capsule:
- Mono-Agent 10 10 surfactant diiglycerides capric, caprilic acid 1
- Example 4 is comparable to Example 4 carried out with R, S amisulpride, under the same dissolution conditions at pH2, 65% of the active principle is dissolved in 10 min.
- Example 9 semi-solid suspension containing
- the active principle is introduced with stirring into the liquid absorption promoter at 50 ° C.
- the mixture is put in capsule.
- the dissolution is rapid and complete.
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000602033A JP2002538094A (ja) | 1999-03-04 | 2000-03-01 | ベンズアミドおよび少なくとも一種の吸収促進剤を含有する経口投与用の医薬組成物 |
CA002362480A CA2362480A1 (fr) | 1999-03-04 | 2000-03-01 | Compositions pharmaceutiques pour l'administration orale comprenant un benzamide et au moins un promoteur d'absorption |
AU29228/00A AU2922800A (en) | 1999-03-04 | 2000-03-01 | Pharmaceutical compositions for oral administration comprising a benzamide and at least an absorption promoter |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9902680A FR2790388B1 (fr) | 1999-03-04 | 1999-03-04 | Compositions pharmaceutiques comprenant un benzamide et au moins un promoteur d'absorption |
FR99/02680 | 1999-03-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000051563A1 true WO2000051563A1 (fr) | 2000-09-08 |
Family
ID=9542809
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2000/000504 WO2000051563A1 (fr) | 1999-03-04 | 2000-03-01 | Compositions pharmaceutiques pour l'administration orale comprenant un benzamide et au moins un promoteur d'absorption |
Country Status (9)
Country | Link |
---|---|
JP (1) | JP2002538094A (fr) |
AR (1) | AR022819A1 (fr) |
AU (1) | AU2922800A (fr) |
CA (1) | CA2362480A1 (fr) |
CO (1) | CO5440229A1 (fr) |
FR (1) | FR2790388B1 (fr) |
PE (1) | PE20001554A1 (fr) |
UY (1) | UY26050A1 (fr) |
WO (1) | WO2000051563A1 (fr) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2857263A1 (fr) * | 2003-07-09 | 2005-01-14 | Sanofi Synthelabo | Nouvelle composition pharmaceutique solide comprenant de l'amisulpride |
CN101507432B (zh) * | 2009-04-02 | 2012-12-19 | 河北省林业科学研究院 | 香芹酚微乳剂及其生产工艺 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR071375A1 (es) * | 2008-04-22 | 2010-06-16 | Solvay Pharm Gmbh | Formulaciones para ingredientes farmaceuticos activos de permeabilidad deficiente, proceso de preparacion y producto |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0273890A1 (fr) * | 1986-12-22 | 1988-07-06 | Astra Lakemedel Aktiebolag | Une forme d'administration liquide pour l'administration orale d'une substance pharmaceutique |
EP0303445A1 (fr) * | 1987-08-13 | 1989-02-15 | Walton S.A. | Pansement pour l'administration transdermique de clébopride |
JPH01236980A (ja) * | 1988-03-14 | 1989-09-21 | Iseki & Co Ltd | 小米選別装置付き貯留タンク |
FR2753376A1 (fr) * | 1996-09-18 | 1998-03-20 | Synthelabo | Compositions pharmaceutiques comprenant de l'amisulpride et leurs applications therapeutiques |
FR2762213A1 (fr) * | 1997-04-18 | 1998-10-23 | Synthelabo | Composition pharmaceutique a retention gastrique |
-
1999
- 1999-03-04 FR FR9902680A patent/FR2790388B1/fr not_active Expired - Fee Related
-
2000
- 2000-03-01 AU AU29228/00A patent/AU2922800A/en not_active Abandoned
- 2000-03-01 CA CA002362480A patent/CA2362480A1/fr not_active Abandoned
- 2000-03-01 WO PCT/FR2000/000504 patent/WO2000051563A1/fr active Application Filing
- 2000-03-01 JP JP2000602033A patent/JP2002538094A/ja not_active Withdrawn
- 2000-03-01 CO CO00014726A patent/CO5440229A1/es not_active Application Discontinuation
- 2000-03-03 UY UY26050A patent/UY26050A1/es unknown
- 2000-03-03 PE PE2000000186A patent/PE20001554A1/es not_active Application Discontinuation
- 2000-03-03 AR ARP000100941A patent/AR022819A1/es unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0273890A1 (fr) * | 1986-12-22 | 1988-07-06 | Astra Lakemedel Aktiebolag | Une forme d'administration liquide pour l'administration orale d'une substance pharmaceutique |
EP0303445A1 (fr) * | 1987-08-13 | 1989-02-15 | Walton S.A. | Pansement pour l'administration transdermique de clébopride |
JPH01236980A (ja) * | 1988-03-14 | 1989-09-21 | Iseki & Co Ltd | 小米選別装置付き貯留タンク |
FR2753376A1 (fr) * | 1996-09-18 | 1998-03-20 | Synthelabo | Compositions pharmaceutiques comprenant de l'amisulpride et leurs applications therapeutiques |
FR2762213A1 (fr) * | 1997-04-18 | 1998-10-23 | Synthelabo | Composition pharmaceutique a retention gastrique |
Non-Patent Citations (1)
Title |
---|
PATENT ABSTRACTS OF JAPAN vol. 1998, no. 14 31 December 1998 (1998-12-31) * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2857263A1 (fr) * | 2003-07-09 | 2005-01-14 | Sanofi Synthelabo | Nouvelle composition pharmaceutique solide comprenant de l'amisulpride |
WO2005004860A2 (fr) * | 2003-07-09 | 2005-01-20 | Sanofi-Aventis | Nouvelle composition pharmaceutique solide comprenant de l'amisulpride |
WO2005004860A3 (fr) * | 2003-07-09 | 2005-04-14 | Sanofi Aventis | Nouvelle composition pharmaceutique solide comprenant de l'amisulpride |
CN101507432B (zh) * | 2009-04-02 | 2012-12-19 | 河北省林业科学研究院 | 香芹酚微乳剂及其生产工艺 |
Also Published As
Publication number | Publication date |
---|---|
FR2790388A1 (fr) | 2000-09-08 |
AU2922800A (en) | 2000-09-21 |
CA2362480A1 (fr) | 2000-09-08 |
UY26050A1 (es) | 2000-09-29 |
JP2002538094A (ja) | 2002-11-12 |
PE20001554A1 (es) | 2001-03-18 |
AR022819A1 (es) | 2002-09-04 |
CO5440229A1 (es) | 2004-09-30 |
FR2790388B1 (fr) | 2001-04-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2490678B1 (fr) | Capsules ou comprimés enrobés d'un mélange oléagineux d'acides gras | |
EP1242047B1 (fr) | Formulations galeniques du fenofibrate et leur procede d'obtention | |
AU2007265836B8 (en) | An effective pharmaceutical carrier for poorly bioavailable drugs | |
WO2002053131A1 (fr) | Compositions pharmaceutiques colloïdales micellaires renfermant un principe actif lipophile | |
CN105120842B (zh) | 包含脂质化合物、甘油三酯和表面活性剂的组合物以及使用它们的方法 | |
WO1996033697A1 (fr) | Formulation auto-emulsionnable formant une emulsion huile dans l'eau | |
CA2434641A1 (fr) | Preparations de microemulsion chimiotherapeutique de paclitaxel presentant une meilleure biodisponibilite orale | |
WO2008073731A2 (fr) | Formes galéniques de microémulsion de valsartan et procédés de préparation de celles-ci | |
FR2950253A1 (fr) | Nanocapsules lipidiques, procede de preparation et utilisation comme medicament | |
EP0927026A1 (fr) | Compositions pharmaceutiques comprenant de l'amisulpride et leurs applications therapeutiques | |
EP1244427B1 (fr) | Compositions pharmaceutiques destinees a une administration par voie orale | |
WO2000051563A1 (fr) | Compositions pharmaceutiques pour l'administration orale comprenant un benzamide et au moins un promoteur d'absorption | |
TW200526200A (en) | Therapeutic compositions | |
EP1691808B1 (fr) | Composition pharmaceutique destinee a l'administration orale d'un derive de pyrazole-3-carboxamide | |
FR2842734A1 (fr) | Procede pour diminuer la variabilite de la biodisponibilite d'un medicament a administration orale et compositions pharmaceutiques a administration orale | |
EP0726760B1 (fr) | Formulation auto-emulsionnable formant une huile dans eau | |
CN104958275A (zh) | 脂肪酸油混合物的包衣胶囊和包衣片剂 | |
FR2715067A1 (fr) | Nouvelle forme galénique de dérivés de 5-nitro-imidazole efficace pour le traitement des parasitoses et des infections de l'ensemble du tractus gastro-intestinal. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 29228/00 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2362480 Country of ref document: CA Ref country code: CA Ref document number: 2362480 Kind code of ref document: A Format of ref document f/p: F |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2000 602033 Kind code of ref document: A Format of ref document f/p: F |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase |